
Memo Therapeutics and Ono Pharmaceutical enter partnership
Under the terms of the agreement, Memo Therapeutics AG will leverage its microfluidic single-cell molecular cloning and screening technologies to...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

C4X Discovery Holdings inks $402m deal with AstraZeneca
Under the agrrement, C4X Discovery Holdings plc (C4XD) will receive pre-clinical milestone payments worth up to $16m ahead of the first clinical...

Rewind Therapeutics extends Series A financing
The company, founded by CD3 (Leuven, Belgium) and Axxam S.p.A. (Milan), did not want to reveal the exact amount added to the €15.2m in its 2018...

CatalYm GmbH raises €50m to push visugromab development
Following a €60m Series B financing in 2020, Martinsried-based CatalYm GmbH announced the closing of a Series C financing round of €50m. The...

Novo Holdings invests into standardisation of LC-MS-based proteomics
Novo Holdings, the investment arm of Nordisk A/S has invested €40m in the eight-years-old clinical proteomics specialist Ecosep Aps to benefit from...

Benefits of booster campaigns questionable
While Pfizer Inc and BioNTech SE financial outlooks in February prognosed more than $50bn in combined coronavirus disease (COVID-19) vaccine sales in...